Training and Resources

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA® (pembrolizumab) in metastatic colorectal cancer (CRC)

KEYNOTE-177: 5-Year Update with Dr. Kai-Keen Shiu

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYTRUDA® (pembrolizumab) KEYNOTE-177 clinical data presentation

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Review of KEYNOTE-177 study and outcomes

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Testing for MSI/MMR status at diagnosis; a key for the 1L treatment of eligible patients with advanced CRC

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYTRUDA® monotherapy

A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-mediated adverse events

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYTRUDA mode of action

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Patient education and support materials

KEYTRUDA® (pembrolizumab) monotherapy patient diary

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

More information about KEYTRUDA® (pembrolizumab) in metastatic CRC

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website